Cargando…
Functional impact and molecular binding modes of drugs that target the PI3K isoform p110δ
Targeting the PI3K isoform p110δ against B cell malignancies is at the mainstay of PI3K inhibitor (PI3Ki) development. Therefore, we generated isogenic cell lines, which express wild type or mutant p110δ, for assessing the potency, isoform-selectivity and molecular interactions of various PI3Ki chem...
Autores principales: | Hassenrück, Floyd, Farina-Morillas, Maria, Neumann, Lars, Landini, Francesco, Blakemore, Stuart James, Rabipour, Mina, Alvarez-Idaboy, Juan Raul, Pallasch, Christian P., Hallek, Michael, Rebollido-Rios, Rocio, Krause, Günter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241892/ https://www.ncbi.nlm.nih.gov/pubmed/37277510 http://dx.doi.org/10.1038/s42003-023-04921-z |
Ejemplares similares
-
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
por: Krause, Günter, et al.
Publicado: (2018) -
Relevant Cytokines in the B Cell Lymphoma Micro-Environment
por: Krause, Günter, et al.
Publicado: (2020) -
Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors
por: Hassenrück, Floyd, et al.
Publicado: (2018) -
Antigen receptor signalling: a distinctive role for the p110δ isoform of PI3K
por: Okkenhaug, Klaus, et al.
Publicado: (2007) -
Deficiency of p110δ Isoform of the Phosphoinositide 3 Kinase Leads to Enhanced Resistance to Leishmania donovani
por: Khadem, Forough, et al.
Publicado: (2014)